SCHEMBL4763705

SCHEMBL4763705

COc1cc2sc(C(=O)O)c(OCC3C4CCC(C4)C3C)c2cc1OC

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
STING1 Q86WV6 13/20 0.41
L3MBTL1 Q9Y468 2/20 0.33
PIK3CD O00329 1/20 0.33
MAPT P10636 1/20 0.32
EDNRA P25101 1/20 0.32
DYRK1A Q13627 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
ALOX15 P16050 1/20 0.31
HSD17B10 Q99714 1/20 0.31
GPR55 Q9Y2T6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6021022 0.83 STING1 (0.49) STING1L3MBTL1MAPTDYRK1AALDH1A1
SCHEMBL6020793 0.81 MAPT (0.34) STING1MAPTALDH1A1GAAHSD17B10
SCHEMBL6020839 0.81 STING1 (0.47) STING1PIK3CDMAPTDYRK1AALDH1A1
SCHEMBL6021329 0.81 STING1 (0.47) STING1L3MBTL1PIK3CDDYRK1A
SCHEMBL6021255 0.80 STING1 (0.46) STING1MAPTDYRK1AALDH1A1HSD17B10
SCHEMBL6021540 0.80 STING1 (0.46) STING1MAPTDYRK1AALDH1A1HSD17B10
SCHEMBL4762800 0.77 STING1 (0.46) STING1L3MBTL1MAPTEDNRADYRK1A
SCHEMBL4769989 0.77 STING1 (0.43) STING1L3MBTL1EDNRADYRK1AALDH1A1
SCHEMBL6020606 0.77 STING1 (0.44) STING1L3MBTL1
SCHEMBL9023626 0.75 STING1 (0.54) STING1L3MBTL1EDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287469-A1 Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation DIACOVO THOMAS G 2008-11-20 US claimed
EP-1885356-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION ICOS CORPORATION (US) 2008-02-13 EP claimed
WO-2006089106-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION ICOS CORPORATION (US) 2006-08-24 WO claimed
US-20080287469-A1 Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation DIACOVO THOMAS G 2008-11-20 US disclosed
EP-1885356-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION ICOS CORPORATION (US) 2008-02-13 EP disclosed
WO-2006089106-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION ICOS CORPORATION (US) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287469-A1 Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation PI4KB, PIK3CA, PI4KA STING1 915/4885L3MBTL1 3837/4885PIK3CD 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.